Glenmark Life Sciences IPO details (27 – 29 July), (Price: 695-720)
Listing date and Listing Price of Glenmark Life Sciences IPO:
- Glenmark Life Sciences IPO listed on BSE and NSE exchanges on – Click Here
- Listing Price of Glenmark Life Sciences IPO on NSE – Click Here
- Listing Price of Glenmark Life Sciences IPO on BSE – Click Here
Grey Market premium (GMP) price of Glenmark Life Sciences IPO :
Grey Market premium (GMP) price of Glenmark Life Sciences IPO is Rs 250. Grey Market premium (GMP) of Glenmark Life Sciences IPO means, unofficially if someone buys or sells his application at a fixed rate irrespective of listing price. (Source : ipowatch.in) Check latest GMP of all IPOs.
Glenmark Life Sciences IPO Allotment link status on Kfintech:
Check the allotment status of Glenmark Life Sciences IPO on these three links given by Kfintech.
- Glenmark Life Sciences IPO Allotment Link 1 – https://kosmic.kfintech.com/ipostatus/
- Glenmark Life Sciences IPO Allotment Link 2 – https://kcas.kfintech.com/ipostatus/
- Glenmark Life Sciences IPO Allotment Link 3 -https://evault.kfintech.com/ipostatus/
Glenmark Life Sciences IPO Allotment link status on Kfintech can be checked by Application No or DPID/Client ID or PAN and enter ‘Captcha’.
Glenmark Life Sciences IPO Allotment link status on Kprism app:
KPRISM, an app by KFin Technologies Pvt Ltd (Registrar of this IPO) can be downloaded from Play Store on mobile or Tab.
- Download KPRISM app by KFin Tech.
- Select IPO Status (No need to do login or register to check IPO allotment)
- Select Glenmark Life Sciences IPO from the list.
- Enter Application Number or DPID Client ID or PAN, then Submit.
- The allotment status of Glenmark Life Sciences IPO, with no. of shares allotted will come.
Glenmark Life Sciences IPO subscription status details:
|QIB (Qualified Institl. Bidders)||NIB (Non-institutional Investor)||RII (Retail Individual Investor)||Employee category||Total No. of times applied|
|No. of shares offered|
Glenmark Life Sciences IPO highlights:
|Glenmark Life Sciences IPO bid Opens on||27 July 2021, Wednesday|
|Glenmark Life Sciences IPO bid Closes on||29 July 2021, Friday|
|Post issue Modification Period||30-July-2021 (10.00 A.M. to 11.00 A.M.)|
|Cut-off time for UPI Mandate Confirmation||30-July-2021 (upto 12:00 PM)|
|Issue type||100% Book Building|
|Glenmark Life Sciences IPO issue size||₹ 1513.60 Cr|
|Face value of each equity share||Rs. 2|
|Glenmark Life Sciences IPO Price band||Rs.695 to Rs.720 per share|
|Glenmark Life Sciences IPO market lot||20 equity shares and multiples of 20|
|Glenmark Life Sciences IPO minimum order quantity||20 equity shares|
|Pre IPO equity share of promoters of Glenmark Life Sciences||____%|
|Post IPO paid-up equity share of promoters of Glenmark Life Sciences||____%|
|QIB portion reservation in Glenmark Life Sciences IPO||50 %|
|NIB portion reservation in Glenmark Life Sciences IPO||15 %|
|Retail portion reservation in Glenmark Life Sciences IPO||35 %|
|Retail individual bidder can apply in Glenmark Life Sciences IPO||up to 2 lakh (200,000) – Maximum 13 Lot|
|Retail individual discount in Glenmark Life Sciences IPO||NA|
|Employees can apply in Glenmark Life Sciences IPO||up to 5 lakh (500,000)|
|Employees Reservation in Glenmark Life Sciences IPO||NA|
|Employees Discount in Glenmark Life Sciences IPO||NA|
|Listing of Glenmark Life Sciences at Exchanges||NSE, BSE|
|Fund raised from Anchor Investors in Pre-IPO of Glenmark Life Sciences||NA|
|Registrar of Glenmark Life Sciences IPO issue||Kfin Technologies Private Limited|
Glenmark Life Sciences IPO important dates regarding bidding, allotment, listing, refund etc. :
The probable dates regarding bidding, allotment, listing, refund of Glenmark Life Sciences IPO are mentioned below.
|Glenmark Life Sciences IPO opens on||27.07.2021|
|Glenmark Life Sciences IPO Closes on||29.07.2021|
|Allotment basis date of Glenmark Life Sciences IPO||03.08.2021|
|Money refund date of Glenmark Life Sciences IPO||04.08.2021|
|Shares of Glenmark Life Sciences in Demat Account||05.08.2021|
|Glenmark Life Sciences IPO listing date on NSE, BSE||06.08.2021|
How much shares of Glenmark Life Sciences IPO are being offered?
|Type of Issue (Fresh / OFS)||No. of Equity shares offered||Amount of Equity shares|
|Total Issue size||₹ 1513.60 Crore|
|Fresh Issue size||–||₹ 1060 Crore|
|Offer for Sale (OFS)||–||₹ 453.60 Crore|
Glenmark Life Sciences financial statements details:
|(₹ million)||(₹ million)||(₹ million)|
|Profit After Tax||3,515.81||3,130.98||1,955.92|
IPO Red Herring Prospectus (RHP) of Glenmark Life Sciences:
Objectives of the Glenmark Life Sciences IPO Issue: (Source – RHP)
Objects of the Fresh Offer
Our Company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:
1.Payment of outstanding purchase consideration to the Promoter for the spin-off of the API business from the Promoter into our Company pursuant to the Business Purchase Agreement dated October 9, 2018
2.Funding capital expenditure requirements; and
3.General corporate purposes
Business of Glenmark Life Sciences: (Source – RHP)
We are a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (“APIs”) in chronic therapeutic areas, including cardiovascular disease (“CVS”), central nervous system disease (“CNS”), pain management and diabetes (Source: Frost & Sullivan Report). We also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas.
Our API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which we believe reflects our capability to branch into other high value products. We have strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology) (Source: Frost & Sullivan Report).
We are also increasingly providing contract development and manufacturing operations(“CDMO”) services to a range of multinational and specialty pharmaceutical companies. We are a research and development (“R&D”)-driven API manufacturer, focused on undertaking dedicated R&D in our existing products and in areas where we believe there is growth potential in the future. We believe that maintaining high standards of process innovation and quality in our R&D and manufacturing operations is critical to our brand and maintenance of long-term relationships with our customers.
Go Back to – IPO Dashboard for other IPOs:
Kindly verify from RHP and concerned company for any clarification.